hrp0097p2-120 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Identification of 2 new heterozygous ACAN variants in a 3-years-old boy with short stature who presented with advanced bone age: a case report

Rezgui Somia , Lahmari Rachid , Khensal Sabrina

Aggrecan, encoded by the ACAN gene, is the main proteoglycan component in the extracellular cartilage matrix. A heterozygous ACAN mutation has been reported as a major cause of idiopathic short stature, it causes an accelerated bone age maturation and premature growth cessation. Recently, the effectiveness of GH treatment for achieving an appropriate adult height has been reported in several cases with ACAN mutations. We report the case of a 3 years and 2 months old boy, with ...

hrp0095p1-540 | Multisystem Endocrine Disorders | ESPE2022

Screening for hypoparathyroidism in beta thalassemia major: About a series from Constantine

Khensal Sabrina , Bouhelassa Amina , Benmohammed Karima , Nouri Nassim

Introduction: Endocrine complications observed in patients with thalassemia major (TM) are mainly secondary to martial overload. Hypoparathyroidism (HPT) is a late and rare complication, typical of the 2nd decade of life in transfusion-dependent thalassemia patients (TDT). It is usually associated with other iron overload conditions (diabetes, hypogonadism, heart failure, etc.). The incidence of PTH varies from 1.2% to 20% depending on the center. Men are more...

hrp0095p2-30 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Long QT revealing hypoparathyroidism in a B thalassemic major

Khensal Sabrina , Bouhelassa Amina , Benmohammed Karima , Nouri Nassim

Introduction: Beta thalassemia major (BTM), a hereditary haemoglobinopathy due to a deficiency in the synthesis of beta-globin, leads in the homozygous state to severe anemia requiring regular transfusions associated with chelator treatment. The endocrine complications encountered in BTM, secondary to martial overload by direct damage to the glandular parenchyma, continue to be observed in our consultations, although early and well-managed chelation can reduce...

hrp0095p2-199 | Growth and Syndromes | ESPE2022

Challenges of late diagnosis of turner's syndrome: a case report of 18 women

Khensal Sabrina , Boukri Asma , Bouhelassa Amina , Nouri Nassim

Introduction: Patients with Turner syndrome (TS) diagnosed beyond the age of 12 years present a real challenge for therapeutic management. Indeed, compromises must be made between the progressive induction of puberty and an efficient treatment with growth hormone to have the best possible results.Patients and methods: Our study concerns 18 cases of patients followed for ST in endocrinology consultation (CHU Constantine-A...

hrp0095p2-201 | Growth and Syndromes | ESPE2022

Association between Turner Syndrom and GH deficiency: 04 case

Khensal Sabrina , Bouhelassa Amina , Boukri Asma , Nouri Nassim

Introduction: Turner Syndrom (TS) is one of the most common chromosomic abnormalities. It associates almost constantly an ovarian dysgenesis and a growth delay (GD). The GD is often secondary to a peripheral resistance to the growth hormone (GH). The GH deficiency (GHD) is a rare cause of growth delay, the association between these two condition is even rarer.Patients and methods: We describe here the cases of 4 patients...

hrp0094p2-419 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2021

A late revelation of Sexual differentiation disorder 46XX due to 11 beta hydroxylase deficiency

Sabrina Khensal , Amina Bouhlassa , Chahinez Habi , Nassim Nouri

Introduction: Congenital adrenal hyperplasia due to 11 beta hydroxylase deficiency, is an autosomal recessive pathology that represents 5 to 8% of congenital adrenal hyperplasia. The predominant symptoms of this disorder are androgen excess’ features, including masculinization of female newborns and precocious puberty in male children. Approximately, two thirds of patients also have hypertension, which may or may not be associated with mineralocorticoid excess, hypokale...